[PDF][PDF] ENCORE 601: A Phase 2 study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with melanoma
ML Johnson, R Gonzalez, M Opyrchal, D Gabrilovich… - Sepsis, 2017 - cms.syndax.com
BACKGROUND• ENT is an oral, class I selective histone deacetylase inhibitor shown
preclinically to enhance the activity of immune checkpoint blockade through the reduction of
functionally immunosuppressive myeloid-derived suppressor cells (MDSCs) and regulatory
T cells (Figure 1). 1-3
preclinically to enhance the activity of immune checkpoint blockade through the reduction of
functionally immunosuppressive myeloid-derived suppressor cells (MDSCs) and regulatory
T cells (Figure 1). 1-3
Preliminary results of ENCORE 601, a phase 1b/2, open-label study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with non-small cell …
ML Johnson, AA Adjei, SS Ramalingam, PA Janne… - 2016 - ascopubs.org
e20659 Background: Treatment with single agent PD-1 blockade improves survival in
patients with chemotherapy-refractory NSCLC, yet only a minority respond. Rational
combination approaches are needed to improve frequency, depth, and durability of
response. ENT is an oral, class I selective histone deacetylase (HDAC) inhibitor. In animal
models, ENT selectively reduces immunosuppressive myeloid derived suppressor cells
(MDSCs) and enhances response to immune checkpoint blockade. ENCORE 601 is a …
patients with chemotherapy-refractory NSCLC, yet only a minority respond. Rational
combination approaches are needed to improve frequency, depth, and durability of
response. ENT is an oral, class I selective histone deacetylase (HDAC) inhibitor. In animal
models, ENT selectively reduces immunosuppressive myeloid derived suppressor cells
(MDSCs) and enhances response to immune checkpoint blockade. ENCORE 601 is a …